Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease

G. Marino, V. K. Rustgi, G. Salzberg, L. B. Johnson, P. C. Kuo, J. S. Plotkin, D. A. Flockhart

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Hepapoietin is a naturally occurring cytokine that promotes hepatocyte growth. Animal studies have suggested that hepapoietin and hepatocyte growth factor have a potential role in the prevention and management of liver diseases. However, human studies have been lacking. Aim: To evaluate the safety and pharmacokinetics of single escalating doses of hepapoietin in patients with chronic liver disease. Methods: An open-label, single escalating dose trial with five different doses of hepapoietin (1. 3, 10. 30 and 100 mg) was performed. Adults with chronic, compensated, non-viral liver disease were included. Liver function tests were obtained before dosing, 24 h after hepapoietin administration and on days 4. 7, 30 and 45. All patients were followed for 45 days. Results: Twenty-five subjects received hepapoietin, with five subjects each at 1, 3, 10, 30 and 100 mg of hepapoietin. Significant decreases occurred in total bilirubin, ammonia, partial thromboplastin time and cholesterol levels overall, and both high-density and low-density lipoprotein cholesterol showed a downward trend. An increase in albumin was observed at the 30 mg dose level. Slight decreases in haemoglobin and red blood cell levels were observed at day 4, but returned to normal levels immediately thereafter. Child-Pugh scores from day 0 to day 7 were improved in 24%, stable in 64% and worse in 12% of patients. Hepatic encephalopathy displayed changes from day 0 to day 45 with improvement in 16%, no change in 80% and worsening in 4%. Conclusions: Hepapoietin in doses up to 100 mg is safe for use in humans. Potential benefits are suggested by significant decreases in bilirubin, ammonia, partial thromboplastin time and cholesterol levels and an increase in albumin. Further studies with multiple dosing regimens are needed to identify the clinical utility of hepapoietin in the management of chronic liver disease.

Original languageEnglish (US)
Pages (from-to)235-242
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume16
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Liver Diseases
Chronic Disease
Pharmacokinetics
Partial Thromboplastin Time
Bilirubin
Ammonia
Albumins
Cholesterol
Hepatocyte Growth Factor
Hepatic Encephalopathy
Liver Function Tests
LDL Cholesterol
Hepatocytes
Hemoglobins
Erythrocytes
Cytokines
Safety
Growth

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Marino, G., Rustgi, V. K., Salzberg, G., Johnson, L. B., Kuo, P. C., Plotkin, J. S., & Flockhart, D. A. (2002). Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Alimentary Pharmacology and Therapeutics, 16(2), 235-242. https://doi.org/10.1046/j.1365-2036.2002.01110.x

Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. / Marino, G.; Rustgi, V. K.; Salzberg, G.; Johnson, L. B.; Kuo, P. C.; Plotkin, J. S.; Flockhart, D. A.

In: Alimentary Pharmacology and Therapeutics, Vol. 16, No. 2, 2002, p. 235-242.

Research output: Contribution to journalArticle

Marino, G, Rustgi, VK, Salzberg, G, Johnson, LB, Kuo, PC, Plotkin, JS & Flockhart, DA 2002, 'Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease', Alimentary Pharmacology and Therapeutics, vol. 16, no. 2, pp. 235-242. https://doi.org/10.1046/j.1365-2036.2002.01110.x
Marino, G. ; Rustgi, V. K. ; Salzberg, G. ; Johnson, L. B. ; Kuo, P. C. ; Plotkin, J. S. ; Flockhart, D. A. / Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. In: Alimentary Pharmacology and Therapeutics. 2002 ; Vol. 16, No. 2. pp. 235-242.
@article{eca75030dc244f2cbddf217c6ddf3c80,
title = "Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease",
abstract = "Background: Hepapoietin is a naturally occurring cytokine that promotes hepatocyte growth. Animal studies have suggested that hepapoietin and hepatocyte growth factor have a potential role in the prevention and management of liver diseases. However, human studies have been lacking. Aim: To evaluate the safety and pharmacokinetics of single escalating doses of hepapoietin in patients with chronic liver disease. Methods: An open-label, single escalating dose trial with five different doses of hepapoietin (1. 3, 10. 30 and 100 mg) was performed. Adults with chronic, compensated, non-viral liver disease were included. Liver function tests were obtained before dosing, 24 h after hepapoietin administration and on days 4. 7, 30 and 45. All patients were followed for 45 days. Results: Twenty-five subjects received hepapoietin, with five subjects each at 1, 3, 10, 30 and 100 mg of hepapoietin. Significant decreases occurred in total bilirubin, ammonia, partial thromboplastin time and cholesterol levels overall, and both high-density and low-density lipoprotein cholesterol showed a downward trend. An increase in albumin was observed at the 30 mg dose level. Slight decreases in haemoglobin and red blood cell levels were observed at day 4, but returned to normal levels immediately thereafter. Child-Pugh scores from day 0 to day 7 were improved in 24{\%}, stable in 64{\%} and worse in 12{\%} of patients. Hepatic encephalopathy displayed changes from day 0 to day 45 with improvement in 16{\%}, no change in 80{\%} and worsening in 4{\%}. Conclusions: Hepapoietin in doses up to 100 mg is safe for use in humans. Potential benefits are suggested by significant decreases in bilirubin, ammonia, partial thromboplastin time and cholesterol levels and an increase in albumin. Further studies with multiple dosing regimens are needed to identify the clinical utility of hepapoietin in the management of chronic liver disease.",
author = "G. Marino and Rustgi, {V. K.} and G. Salzberg and Johnson, {L. B.} and Kuo, {P. C.} and Plotkin, {J. S.} and Flockhart, {D. A.}",
year = "2002",
doi = "10.1046/j.1365-2036.2002.01110.x",
language = "English (US)",
volume = "16",
pages = "235--242",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease

AU - Marino, G.

AU - Rustgi, V. K.

AU - Salzberg, G.

AU - Johnson, L. B.

AU - Kuo, P. C.

AU - Plotkin, J. S.

AU - Flockhart, D. A.

PY - 2002

Y1 - 2002

N2 - Background: Hepapoietin is a naturally occurring cytokine that promotes hepatocyte growth. Animal studies have suggested that hepapoietin and hepatocyte growth factor have a potential role in the prevention and management of liver diseases. However, human studies have been lacking. Aim: To evaluate the safety and pharmacokinetics of single escalating doses of hepapoietin in patients with chronic liver disease. Methods: An open-label, single escalating dose trial with five different doses of hepapoietin (1. 3, 10. 30 and 100 mg) was performed. Adults with chronic, compensated, non-viral liver disease were included. Liver function tests were obtained before dosing, 24 h after hepapoietin administration and on days 4. 7, 30 and 45. All patients were followed for 45 days. Results: Twenty-five subjects received hepapoietin, with five subjects each at 1, 3, 10, 30 and 100 mg of hepapoietin. Significant decreases occurred in total bilirubin, ammonia, partial thromboplastin time and cholesterol levels overall, and both high-density and low-density lipoprotein cholesterol showed a downward trend. An increase in albumin was observed at the 30 mg dose level. Slight decreases in haemoglobin and red blood cell levels were observed at day 4, but returned to normal levels immediately thereafter. Child-Pugh scores from day 0 to day 7 were improved in 24%, stable in 64% and worse in 12% of patients. Hepatic encephalopathy displayed changes from day 0 to day 45 with improvement in 16%, no change in 80% and worsening in 4%. Conclusions: Hepapoietin in doses up to 100 mg is safe for use in humans. Potential benefits are suggested by significant decreases in bilirubin, ammonia, partial thromboplastin time and cholesterol levels and an increase in albumin. Further studies with multiple dosing regimens are needed to identify the clinical utility of hepapoietin in the management of chronic liver disease.

AB - Background: Hepapoietin is a naturally occurring cytokine that promotes hepatocyte growth. Animal studies have suggested that hepapoietin and hepatocyte growth factor have a potential role in the prevention and management of liver diseases. However, human studies have been lacking. Aim: To evaluate the safety and pharmacokinetics of single escalating doses of hepapoietin in patients with chronic liver disease. Methods: An open-label, single escalating dose trial with five different doses of hepapoietin (1. 3, 10. 30 and 100 mg) was performed. Adults with chronic, compensated, non-viral liver disease were included. Liver function tests were obtained before dosing, 24 h after hepapoietin administration and on days 4. 7, 30 and 45. All patients were followed for 45 days. Results: Twenty-five subjects received hepapoietin, with five subjects each at 1, 3, 10, 30 and 100 mg of hepapoietin. Significant decreases occurred in total bilirubin, ammonia, partial thromboplastin time and cholesterol levels overall, and both high-density and low-density lipoprotein cholesterol showed a downward trend. An increase in albumin was observed at the 30 mg dose level. Slight decreases in haemoglobin and red blood cell levels were observed at day 4, but returned to normal levels immediately thereafter. Child-Pugh scores from day 0 to day 7 were improved in 24%, stable in 64% and worse in 12% of patients. Hepatic encephalopathy displayed changes from day 0 to day 45 with improvement in 16%, no change in 80% and worsening in 4%. Conclusions: Hepapoietin in doses up to 100 mg is safe for use in humans. Potential benefits are suggested by significant decreases in bilirubin, ammonia, partial thromboplastin time and cholesterol levels and an increase in albumin. Further studies with multiple dosing regimens are needed to identify the clinical utility of hepapoietin in the management of chronic liver disease.

UR - http://www.scopus.com/inward/record.url?scp=0036171877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036171877&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2002.01110.x

DO - 10.1046/j.1365-2036.2002.01110.x

M3 - Article

C2 - 11860406

AN - SCOPUS:0036171877

VL - 16

SP - 235

EP - 242

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 2

ER -